Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib Combined with PD-1 and TACE for Advanced HCC
NCT05262959Phase 2Completed
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Dec 2021
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of donafenib in hepatocellular carcinoma (HCC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Progression-free survival at 1 year. Started Dec 2021; status: completed.
02
Drugs
donafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05262959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05262959.